Biographies for Dr. Lindsay A. Rosenwald’s websiteFreelance writing assignmentBy Vanessa Angulo

The biotechnology industry will grow considerably in the next two decades. Dr. Lindsay A. Rosenwald believes in responding to the need for safe effective remedies with medical improvements developed by his companies. Dr. Rosenwald's discoveries within the Paramount Group of Companies will lead to the effectual treatment of diseases, such as cancer and heart disease. Dr. Rosenwald knows that the small-scale biotechnology and life-science companies, like the institutions he has started within the Paramount Group of Companies, will develop inventive technologies. Under the direction of Dr. Rosenwald, the Paramount Group of Companies has developed select group of products, bringing concentrated focus to those products and securing their favorable stance in the biotechnological field.

Dr. Rosenwald has been the leader and developer of the following companies, which are included in Paramount Group of Companies: Paramount BioSciences, a drug/health care expansion and investment firm that aids new biotechnology companies around the world. Paramount Corporate Development, an organization that makes medical and corporate development achievable for Paramount’s portfolio companies. Paramount BioCapital, a FINRA-registered broker-dealer that generates funds for Paramount’s portfolio companies and have grossed nearly $950,000,000 since its inception. Dr. Rosenwald is the President of the Rosenwald Foundation, a benevolent association in New York, which supports remarkable scientific individuals in their constant efforts to further the progress of biotechnology. The Rosenwald Foundation has also contributed millions to many notable schools and institutions. Dr. Rosenwald is also affiliated with the Columbia-Presbyterian Health Sciences Advisory Counsel. The Columbia Presbyterian Health Sciences Advisory Council presents two Awards for Distinguished Services yearly to mavericks that have made a great impact on the community's health and welfare.

Dr. Lindsay A. Rosenwald attained his medical degree from Temple University School of Medicine in 1983. He has been key in the creation and intercontinental expansion of numerous public and private biotechnology and life science companies since then. Dr. Rosenwald has a Bachelor of Science degree in finance from Pennsylvania State University. He has been a trailblazer in the world of biotechnology on Wall Street for over 20 years. Dr. Rosenwald was a Physician Analysts on Wall Street in 1986. Using his education in those industries he was led to form Paramount Biocaptial in 1991. He is believed to be one of the world's most productive entrepreneurs in the history of the biotechnological industry.

Dr. Lindsay A. Rosenwald has been a prosperous pharmaceutical and biotechnology financier for over a decade. His skills originated within his extensive pharmaceutical/biomedical business and investment experience. Such experience includes investment banking, venture capital, merchant banking and asset management. Dr. Rosenwald has given many careers for MDs, PhDs, MBAs, attorneys and related professionals by presiding over and astutely managing the Paramount Group of Companies.

Dr. Rosenwald holds the record for the most capital ever paid for a medication not yet finalized in clinical development. In 2009 Cougar Biotechnology, company founded by Dr. Rosenwald, was sold to Johnson and Johnson for an unprecedented 1 billion dollars. The transaction hinged on a medication that had completed phase 2 in clinical trials for prostate cancer, but had not yet completed phase 3 in clinical trials. The Paramount portfolio companies currently have multitude of compounds in clinical trials. A cancer drug to treat a rare form of deadly leukemia created by PolaRx BioPharmaceuticals, a portfolio company of the Paramount Group, received final marketing authorization only 30 months after the first patient was treated in a clinical trial, setting a record for the biotechnology industry. Dr. Rosenwald's companies have changed the biotechnology industry and will continue to change the industry in the years to come.